Recombinant ITGA4 (Natalizumab Biosimilar) antibody
Quick Overview for Recombinant ITGA4 (Natalizumab Biosimilar) antibody (ABIN7795116)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Natalizumab Biosimilar, Integrin alpha 4 Monoclonal Antibody
-
Characteristics
- Natalizumab Biosimilar uses the same protein sequences as the therapeutic antibody natalizumab. Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human Integrin alpha 4
-
-
anti-ITGA4 (Natalizumab Biosimilar) antibody
Research Grade Reactivity: Human FACS Host: Humanized Monoclonal unconjugated Recombinant Antibody
anti-ITGA4 (Natalizumab Biosimilar) antibodyReactivity: Human FACS, BR Host: Rabbit Chimeric unconjugated Recombinant Antibody
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- ITGA4 (Natalizumab Biosimilar)
-
Alternative Name
- Natalizumab Biosimilar
-
Target Type
- Biosimilar
Target
-
